Comparison of Conspicuity of Masses and Architectural Distortions Between Wide- and Narrow-angle Digital Breast Tomosynthesis Systems
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT06373354
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT06369246
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT06369259
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Health Benefits of Writing Therapy Among Asian American Cancer Survivors
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 192
- Registration Number
- NCT06367959
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy with Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 300
- Registration Number
- NCT06367972
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of VG2025 Delivered Intraperitoneally in Patients with Advanced Solid Tumors with Carcinomatosis
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT06365918
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT06358430
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06345495
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT06336642
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 880
- Registration Number
- NCT06337097
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath